Evidence map›Paper›PMID 40864703›Full record

ArticleScience advances2025

Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis.

Laura Boccuni, Frieda Marka, Manuel Salzmann, Alessia Schirripa, Elisabeth Ableitner, Magdalena Siller, Mira Brekalo, Patrick Haider, Stefan Stojkovic, Christoph Neumayer and 13 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. [Dual role and therapeutic potential of TREM2 in atherosclerosis].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Laura BoccuniLudwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.ORCID 0000-0002-3229-4520
Frieda MarkaLudwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
Manuel SalzmannCenter for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-5477-3533
Alessia SchirripaInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0001-5446-9136
Elisabeth AbleitnerDepartment of Pharmacology and Toxicology, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.ORCID 0009-0001-7971-9629
Magdalena SillerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-7354-5763
Mira BrekaloDepartment of Internal Medicine II/Cardiology, Medical University of Vienna, Vienna, Austria.ORCID 0009-0008-3210-6973
Patrick HaiderDepartment of Internal Medicine II/Cardiology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-6874-5349
Stefan StojkovicDepartment of Internal Medicine II/Cardiology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4285-5416
Christoph NeumayerDivision of General Surgery, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1407-4185
Tiit ÖrdA.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0002-3098-1749
Karoline KollmannInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0002-7937-4245
Alice AssingerDepartment of Vascular Biology and Thrombosis Research, Centre of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-5670-5910
Thomas DeckerMax Perutz Labs, University of Vienna, Vienna, Austria.ORCID 0000-0001-9683-0620
Thomas KöcherVienna BioCenter Core Facilities GmbH, Wien, Austria.ORCID 0000-0003-0827-1457
Michael B FischerDepartment of Blood Group Serology and Transfusion Medicine (M.B.F.), Medical University of Vienna, Austria.
Marion MußbacherDepartment of Pharmacology and Toxicology, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria.ORCID 0000-0001-5346-6785
Andreas BergthalerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Christian HengstenbergDepartment of Internal Medicine II/Cardiology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8284-2994
Bruno K PodesserLudwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
Minna U KaikkonenA.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-6294-0979
Johann WojtaLudwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
Philipp J HohensinnerLudwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.ORCID 0000-0003-4819-3190

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage-to-foam cell transition is an integral part of atherosclerotic plaque progression. Particularly, oxidized low-density lipoprotein (oxLDL) is a driving factor in foam cell formation, altering macrophage function and metabolism. The aim of our research was to understand the impact of oxLDL-induced mitochondrial reactive oxygen species on macrophage-to-foam cell differentiation. We demonstrate that macrophage oxLDL-derived superoxide modulates mitochondrial metabolic reprogramming, facilitating foam cell formation. Mechanistically, mitochondrial superoxide drives signal transducers and activators of transcription 5 (STAT5) activation, leading to reduced tricarboxylic acid cycle activity. In parallel, mitochondrial superoxide enhances chromatin accessibility at STAT5 target genes, establishing a distinct STAT5 signaling signature in foam cells ex vivo and in human and mouse plaques in vivo. Inhibition of STAT5 during atherosclerosis progression prevents the differentiation of macrophages to mature Trem2

Indexed as

AtherosclerosisFoam CellsMitochondriaReactive Oxygen SpeciesSignal TransductionSTAT5 Transcription FactorAnimalsCell DifferentiationHumansLipoproteins, LDLMacrophagesMiceSuperoxidesLipoproteins, LDLoxidized low density lipoproteinReactive Oxygen SpeciesSTAT5 Transcription FactorSuperoxides

Identifiers

PMID40864703
PMCPMC12383252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.